Prodotti competitors / Area Kite 21 maggio 2024 Modifica Registro ABECMA per ammettere al trattamento i pazienti sottoposti a precedente terapia con CAR T Out of Specification
Prodotti competitors / Area Kite, Area Onco-Ema 29 aprile 2024 FDA approves BMS’ Abecma indication expansion for Multiple Myeloma
Prodotti competitors / Area Kite 23 marzo 2024 US- FDA Oncologic Drugs Advisory Committee (ODAC) Supported Janssen’s Carvykti and BMS’ Abecma Indication Expansion for Multiple Myeloma on Mar. 15, 2024
Prodotti competitors / Area Kite, Area Onco-Ema 22 marzo 2024 EC Decision granted for Abecma (idecabtagene vicleucel) extension of indication in 3L to treat adults with relapsed and refractory multiple myeloma (r/r MM)
Prodotti competitors / Area Onco-Ema, Area Kite 15 marzo 2024 Abecma backed to permit earlier access for R/R Multiple Myeloma Patients
Prodotti competitors / Area Oncology, Area Kite, Area Onco-Ema 25 settembre 2023 Europe: Oncology CHMP Minutes for June 2023
Prodotti competitors / Area Kite 12 giugno 2023 Cell Therapy - CHMP Minutes for the Meeting on 27-30 March 2023
